相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
20.0%
招募中
4
80.0%
暂无批准数据
- Reproductive biologist Francesca Duncan has shown that ovaries become progressively stiffer, more inflamed, and more fibrotic with age, changes that affect egg quality and may elevate ovarian cancer risk. - In April 2026, Duncan published findings that post-menopausal ovaries, long assumed dormant, continue emitting inflammatory signals that could harm health elsewhere in the body. - Duncan's lab is developing an ultrasound-based test to measure ovarian stiffness as a biomarker for aging and fertility outcomes, including IVF prediction. - Building on Duncan's cohesin research, a February 2026 Chinese study found an existing anti-fibrotic drug restored ovarian function in mice and, in early evidence, helped women with primary ovarian insufficiency.
- Scientists broadly agree that biological age is a valid concept distinct from chronological age, measurable through various molecular clocks that track processes like DNA methylation and chronic inflammation. - Epidemiological studies show that accelerated biological aging, as measured by clocks such as GrimAge and iAge, can predict higher risks of cognitive decline, heart disease, and frailty. - Experts warn that consumer-available tests capture only individual facets of aging and are open to misinterpretation, with single age estimates providing limited clinical value without functional health metrics. - Researchers advocate for better consumer education, healthcare professional guidance, or certification systems to ensure biological aging clocks fulfill their potential role in preventative medicine.
- Scientists at the Buck Institute for Research on Aging have demonstrated that an oral small molecule, N-propargylglycine (N-PPG), completely prevents calcium oxalate kidney stone formation and restores normal survival in mice with Primary Hyperoxaluria Type 2 (PH2). - The drug works by blocking the enzyme HYPDH/PRODH2 that drives excess oxalate production while also strengthening mitochondrial resilience through a process called mitohormesis. - In six-month survival studies, untreated PH2 mice died by 15 weeks from kidney failure, while N-PPG-treated mice survived the full 24-week study period with normal kidney function. - This breakthrough offers hope for treating PH2, a rare genetic disorder affecting an estimated 1,700 people in the US with no current therapeutic options beyond organ transplantation.
- Nautilus Biotechnology has launched an Early Access Program for its novel single-molecule proteomics platform, featuring a tau proteoforms assay as the first offering for exclusive researcher groups. - The platform's Iterative Mapping method enables single-molecule analysis of proteins and proteoforms, designed to achieve comprehensive proteome coverage and precisely map post-translational modifications patterns. - Researchers at the Buck Institute for Research on Aging are successfully using the platform to map up to 768 distinct tau proteoforms across brain regions, revealing disease progression patterns. - The program represents a key commercialization milestone, demonstrating the platform's readiness for external use while offering custom assay development partnerships for specific research applications.
- Nautilus Biotechnology successfully installed and tested its first external field evaluation unit at the Buck Institute for Research on Aging, marking a critical milestone for single-molecule proteomics platform deployment. - The collaboration generated highly reproducible tau proteoform data from neurodegenerative disease samples over six months, providing external validation of the company's next-generation proteomics technology. - The proprietary tau proteoform assay can quantify 768 proteoform groups, enabling unprecedented analysis of protein modifications that influence Alzheimer's disease progression. - Initial findings will be presented at the 2025 HUPO World Congress, demonstrating the platform's potential to advance understanding of complex disease biology and neurodegeneration mechanisms.
- A first-of-its-kind clinical trial demonstrates that therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age by an average of 2.61 years as measured by multi-omic biomarkers. - The single-blind, placebo-controlled study published in Aging Cell showed that participants receiving biweekly TPE-IVIG treatment experienced greater biological age reduction compared to those receiving TPE alone (1.32 years). - Patients with poorer baseline health status, including higher levels of circulating bilirubin, glucose, and liver enzymes, saw the greatest reduction in biological age and improvement in biomarkers. - The intervention modulated cellular senescence-associated proteins and restored age-associated shifts in immune cell composition, potentially improving the body's ability to fight infections and age-related diseases.
- The TAME Trial will investigate metformin's potential to prevent age-related diseases like heart disease, cancer, and cognitive decline in healthy older adults. - Metformin, a widely used diabetes drug, has shown anti-inflammatory effects and reduced risk of cancer, dementia, and cardiovascular issues in observational studies. - The trial aims to understand metformin's mechanisms, such as improving cellular energy through autophagy and reducing inflammation and oxidative stress. - Funding for the TAME Trial, estimated at $45-70 million, is primarily sourced from philanthropists and the National Institute on Aging due to metformin's generic status.
